TCRX is trading at $0.94 (+8.99%) after TScan Therapeutics announced positive initial data from Cohort C of its ALLOHA Phase 1 study for TSC-101 in hematologic malignancies.
- The release highlighted promising efficacy and a consistent safety profile using a commercial-ready manufacturing process.
- The clinical update serves as a clear company-specific catalyst, driving the stock's gains despite broader market weakness today.